Study consort diagram (blinatumomab group).^aIntention to receive HSCT (n = 18), intention to receive treatment other than allogeneic HSCT (n = 1), relapse (n = 25), failure to achieve CR/CRh/CRi in first 2 cycles (n = 1). ^bIntention to receive HSCT (n = 5), intention to receive treatment other than allogeneic HSCT (n = 4), relapse (n = 9).